Welcome to the $29 Billion Shroom Boom | Midas Letter RAW ft COMPASS Pathways & NEXE Innovation скачать в хорошем качестве

Welcome to the $29 Billion Shroom Boom | Midas Letter RAW ft COMPASS Pathways & NEXE Innovation

Whether you want to call it the new $29 Billion biotech sector or the Shroom Boom, psychedelics have the potential to give you the trip of your life in more ways than one. 00:00 - Midas Letter RAW 04:20 - Peruvian election & copper supply 05:55 - Copper chart 08:00 - Commodity war between US & China 12:48 - *COMPASS Pathways PLC (NASDAQ:CMPS) interview* 24:00 - Psychedelics & mental health 27:19 - Voxtur Analytics Corp (OTCMKTS:VXTRF, CVE:VXTR) LOI to acquire Benutech 29:20 - James & Ed psilocybin experiences 33:38 - Rritual Superfoods Inc (OTCMKTS:RRSFF, CNSX:RSF) 39:05 - *NEXE Innovation Inc (CVE:NEXE, OTCMKTS:NEXNF) interview* 47:42 - El Salvador approving Crypto as legal tender 49:23 - NEXE Innovation chart 51:00 - CPI shows the fastest inflation since 2008 56:09 - Audience questions 59:03 - Battery metals The New York Times reported that MDMA could successfully treat PTSD… Public companies are undergoing the scientific research necessary to prove psilocybin is more effective than current depression/anxiety medications… Psychedelic stocks are starting to emerge with sky-high potential. Just wait for the once illegal drugs to move out of labs and into doctors’ offices. In this week’s Midas Letter RAW, we discuss our thoughts on the rise of the fungi, James & Eds experiences on them, some commodity/inflation chat and Latin America's influence on copper economics, and of course, some of our favourite stocks to watch. We have 2 exclusive interviews on deck in today's episode: COMPASS Pathways PLC (NASDAQ:CMPS) CEO George Goldsmith We’re excited to talk with the grandaddy and NASDAQ darling of Psychedelics, Compass Pathways. If you don’t already know, Compass is trying to treat serious forms of depression by using psilocybin. Specifically, looking to treat treatment-resistant depression (TRD), which has an 80-90% relapse rate and affects 100 million people worldwide. Compass is currently conducting Phase IIb clinical trials with results expected to be out at the end of FY 2021. This is a very insightful interview and really outlines why CEO George Goldsmith is passionate about the psychedelic space. NEXE Innovation Inc (CVE:NEXE, OTCMKTS:NEXNF) President Ash Guglani NEXE is disrupting the coffee pod industry. All those Nespresso and Keurig pods you have for breakfast (50 billion of them per year) are clogging up landfills with no real regard for what happens to them. NEXE owns the only patented, fully compostable, plant-based, single-serve coffee pods for use in those leading single-serve coffee machines. And according to the CEO, NEXE has perfected the taste and extraction using its customized IP technology. We hope to speak with President Ash Guglani again soon for more company updates and get our hands on a few samples of its NEXE pod - made from plant fibre, compostable polymers, and other compostable materials, with a bamboo casing. (I like the Colombian variety personally 😉 Just sayin') 💻 Website: https://midasletter.com​​​​ 🐦 Twitter: http://bit.ly/MidasLetterTwitter​​​​ 📘 Facebook: http://bit.ly/MidasLetterFacebook​​​​ 📸 Instagram: http://bit.ly/MidasLetterInsta​​​​ 🎙 Podcast: http://bit.ly/MidasLetterPodcast​​​ #ShroomBoom #News​​​ #MidasLetter